China Stocks Slump as Huawei Shakes Sentiment, Drugmakers Plunge
(Bloomberg) -- A gauge of Chinese stocks in Hong Kong posted its biggest two-day drop in 10 months as the arrest of Huawei Technologies Co.'s chief financial officer dealt fragile investor sentiment another blow and deepened uncertainty over China's relations with the U.S.
The Hang Seng China Enterprises Index dropped 2.6 percent, while the Shanghai Composite Index fell 1.7 percent. Technology stocks were among the hardest hit in both markets as Huawei suppliers tumbled. Huawei CFO Wanzhou Meng is facing extradition to the U.S. after her arrest in Vancouver in connection with potential violations by the company of American sanctions on Iran, according to Canada's Department of Justice. Drugmakers tumbled amid concern over price cuts, while the yuan fell for a second day.
"The news on Huawei comes at a bad time when investor sentiment is weak" and when there's lack of reasons to buy the market toward year-end, said Toshihiko Takamoto, a Singapore-based money manager at Asset Management One. "The consensus is that this trade war may drag on for 10 years."
Chinese drug stocks fell the most since 2009 as investors worried the government is driving down prices for their products via a centralized procurement program. The MSCI China Health Care Index plunged 8.4 percent, with Sino Biopharmaceutical Ltd. sliding 16 percent. CSPC Pharmaceutical Group Ltd. and Genscript Biotech Corp. lost more than 11 percent.
The Hang Seng China measure dropped 3.9 percent over two days. Hong Kong's benchmark Hang Seng Index retreated 2.5 percent on Thursday, with AAC Technologies Holdings Inc. and Huawei supplier Sunny Optical Technology Group Co. declining more than 5 percent. ZTE Corp. slid at least 5 percent in Hong Kong and in Shenzhen.
The news on the Chinese tech giant adds to investor skepticism over the progress of China-U.S. trade relations. While selling pressure eased on Wednesday following China's pledge to move quickly on U.S. trade commitments, doubts remain over whether there's been any real breakthrough. When concern flared in November that the U.S. was ramping up a campaign against Huawei, the Shanghai Composite Index slumped, with technology shares heavily hit.
Other index, stock moves:
- Shenzhen Composite Index -2.2%, CSI 300 Index -2.2% with telecom shares the biggest decliners
- Other Huawei suppliers: O-film Tech -4.5%, GettopAcoustic -8.2%
- 10-year sovereign bond yield little changed at 3.32%, the lowest since April 2017
- Foreign investors sells onshore stocks via Hong Kong trading links for the first time in nine days, offloading 4.2b yuan
To contact the reporter on this story: Kana Nishizawa in Hong Kong at knishizawa5@bloomberg.net
To contact the editors responsible for this story: Richard Frost at rfrost4@bloomberg.net, David Watkins, Philip Glamann
©2018 Bloomberg L.P.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.